Clinical Trial Update: Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine [Phase 1, Phase 2]

View source ↗

Summary

Safety and immunogenicity results from a Phase 1/2 trial of a clade C ALVAC-HIV vaccine with gp120 were reported; the study has completed with results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• ALVAC-HIV vaccine (clade C) (canarypox vector-based HIV vaccine)
• gp120 HIV vaccine (HIV gp120 subunit vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-02-18